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TCT-470
Early Hemodynamic Support with Impella 2.5 Improves Survival in Refractory
Cardiogenic Shock After Acute Myocardial Infarction
Brijeshwar Maini1, Srihari Naidu2, Theodore Schreiber3, Simon Dixon4, William
O’Neill5
1PinnacleHealth Cardiovascular Institute, Wormleysburg, PA; 2Winthrop University,
Mineola, NY; 3Detroit Medical Center, Detroit, MI; 4Beaumont Hospital, Detroit,
MI; 5University of Miami, Miami, FL
Background: For AMI complicated by cardiogenic shock (CS), mortality remains high
despite PCI. Percutaneous ventricular assist devices may improve outcomes in AMI
CS by allowing early hemodynamic support.
Methods: Patients supported with the Impella 2.5 between June 2009 and August 2010
for AMI/CS at the USpella sites are reported without pre selection.
Results: 71 consecutive AMI CS patients from 16 institutions were reported. Patients
remained in cardiogenic shock post AMI despite aggressive medical management prior
to Impella support: 85% of patients received PCI, 78% were on one or multiple
inotropes and 42% had already received an IABP. Post Impella support, the
hemodynamics improved significantly including CI (1.9±0.6 L/min/m2 vs 2.7±0.9,
p=0.002), MAP (62±17 mmHg pre-Impella to 92±21 on Impella, p<0.0001), and
PCWP(28±8 mmHg pre-Impella to 21±12 on Impella, p=0.04).Impella 2.5
significantly improved the cardiac power output (0.5±0.2 W pre-Impella to 1.0 ±0.2
on Impella, p=0.0004). The in-hospital survival was 58%. In the subgroup of patient
that received PCI, there was a significantly higher 30-day survival rate for patients
who received the Impella 2.5 early (pre-PCI) compared to patients who received the
Impella 2.5 post-PCI (77% versus 44% respectively, p=0.01)
Timing of Impella Support Versus Outcome in AMI Shock
Conclusion: Impella 2.5 provided excellent hemodynamic support in AMI CS. The
early stabilization with the Impella 2.5 for patient receiving PCI in the context of AMI
CS appears to improve the 30-day survival. For AMI CS patients with no
contraindications to Impella 2.5 placement,support should be initiated as early as
possible to improve outcomes.
TCT-471
Radial versus Femoral Approach in Primary PCI for STEMI with Cardiogenic
Shock – Prospective Comparison
Ivo Bernat, Martin Kacer, Jan Pesek, Jiri Koza, Richard Rokyta
University Hospital, Pilsen, Czech Republic
Background: Radial approach is increasingly used in patients with acute myocardial
infarction (AMI) without cardiogenic shock (CS). It is unknown whether this approach
is feasible and effective also in patients with AMI and CS. The aim of our study was
to compare radial and femoral approach in primary PCI for STEMI with CS.
Methods: From January 2008 to December 2009 all patients with STEMI <12 hours
and signs of CS (systolic blood pressure ≤90mmHg, heart rate >100/min, systemic
hypoperfusion or required inotropes) before primary PCI were enrolled to this
prospective non randomized comparison in our institution. Radial approach (RA) was
used when both wrist arteries were at least weakly palpable.
Results: Fifty six (8,7%) of 643 STEMI pts were enrolled, 27 in RA group and 29 in
femoral (FA) group. Before primary PCI 44% pts in RA group and 72% pts in FA group
were intubated and mechanically ventilated (p=0.05). Cardiac arrest (30% vs 65% pts,
p=0.01) and history of diabetes (11% vs 38%, p=0.02) were more frequent in FA group.
Baseline creatinine (108±25 vs 141±62 mmol/l, p=0.03) and glycemia (11,1±4,8 vs
16,5±7,1mmol/l, p=0.001) were higher in FA group. Other baseline parameters were
not significantly different. Procedural success (final TIMI 3 flow and residual stenosis
<20% - RA 90% vs FA 85%), use of GPI (33% vs 35%) and use of IABP (19% vs
37%) were similar in both groups (p=NS). There was one conversion from RA to FA.
Severe access site bleeding complication (TIMI major bleeding) occured only in FA
group (2/29 vs 0/27, p=NS). Thirty days mortality was 30% in RA group and 48% in
FA group (p=0.19), one year mortality was significantly lower in RA group (37% vs
72%, p=0.001). Overall one year mortality was 55%.
Conclusion: Radial approach was safe, effective and feasible in almost half of our pts
with STEMI and CS treated by primary PCI. This approach had no serious access site
bleeding complications in contrast to FA. One year mortality was lower in RA group.
TCT-472
Gradual decline in the Age Adjusted Mortality Rate from Cardiogenic Shock of
any Cause or in the Setting of ST Elevation Myocardial Infarction in the United
State
Mohammad Reza Movahed, Mertash Hashemzadeh, Mehrnoosh Hashemzadeh
Medicine, The Southern Arizona VA Health Care System and university of arizona
Sarver Heart Center, Tucson, AZ
Background: Recent improvement in the care of critically ill patients should lead to
better outcome. The goal of this study was to evaluate the age adjusted mortality rate
from cardiogenic shock in the United State over last 10 years using a large data base
Methods: The Nationwide Inpatient Sample (NIS) database was utilized to calculate
the age-adjusted mortality rate of cardiogenic shock from 1996 to 2006 based on ICD-
9 coding. Furthermore, we evaluated the same trend in the setting of STEMI
Results: We found gradual decrees in mortality over last 10 years in patient suffering
from cardiogenic shock with or without a diagnosis of STEMI. The age-adjusted
mortality rate from cardiogenic shock was 1,874 per 100,000 in 1996 which declined
to lowest level in of 1,548 per 100.000 in 2006 (p<0.01). This decline was similar in
patients with or without a diagnosis of STEMI
Conclusion: Age adjusted mortality has been gradually declining in patients presenting
with cardiogenic shock over the last 10 years suggesting recent improvement in cardiac
care have paid off.
TCT-473
Suppression of Oxidative Stress in Endovascular Hypothermia Treated Patients
with Acute Myocardial Infarction and Cardiac Arrest
Petr Ostadal1, Andreas Kruger1, Dagmar Vondrakova1, Marek Janotka1, Jan Herget2
1Na Homolce Hospital, Prague, Czech Republic; 2Charles University in Prague, 2nd
Medical Faculty, Prague, Czech Republic
Background: Protective effect of therapeutic hypothermia in cardiac arrest survivors
has been repeatedly shown. Clinical data on therapeutic hypothermia in acute
myocardial infarction (AMI) are, however, still insufficient; the effect of hypothermia
on oxidative stress (OS) and nitric oxide (NO) production in patients with AMI is not
known.
Methods: Ten patients after out-of-hospital cardiac arrest due to AMI were included
into the hypothermia group; all were treated with mild hypothermia using endovascular
system Thermogard XP. Target core temperature 33°C was maintained for 24 hours,
re-warming rate was set at 0.15°C per hour, followed by normothermia of 36.8°C. Ten
patients with AMI, non-complicated by cardiac arrest were assigned to the control
group. Blood samples for measurements of nitrotyrosine (marker of OS) and
nitrates/nitrites (marker of NO production) were taken at admission and then every 6
hours for a total of 54 hours.
Results: The levels of nitrotyrosine were significantly lower in the hypothermia group
in all measurements (P<0.001). Nitrates/nitrites levels were comparable in both groups
in the first 24 hours, during re-warming the levels gradually increased in the
hypothermia group, reaching significant difference between groups in the
normothermia period (P<0.05).
Conclusion: Our results provide indirect evidence that hypothermia may attenuate OS
and possibly also NO production in AMI patients.
TCT-474
Improvements in LV Function and Afterload with TandemHeart for the
Treatment of Refractory Cardiogenic Shock
Michael Tempelhof, Nirat Beohar, Chris Malaisrie, Patrick McCarthy, Charles
Davidson
Cardiology, Northwestern University, Chicago, IL
Background: The TandemHeart percutaneous ventricular assist device (pVAD),
www.JACC.TCTAbstracts2011
B128 JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Cardiogenic Shock, Heart Failure, and Hemodynamic Support
P
O
S
T
E
R
S
